

Development of a second-generation c-MET inhibitor to overcome acquired resistance to first-generation c-MET inhibitors

CMG Pharmaceutical Co.Ltd
CMG Pharma

ONCOLOGY	Candidate
Product Type	Small molecules
Indication	Non-small cell lung cancer (NSCLC)
Target	c-MET
MoA(Mechanism of Action)	Inhibition of acquired resistance mutations that occur after first-line treatment in patients with Met exon 14 skipping mutations
Competitiveness	<ul style="list-style-type: none"> • No drugs have been approved globally for MET alteration indications other than Met exon 14 skipping mutation • The CB series we are developing shows excellent effects not only in acquired resistance(point mutation) but also in Met exon 14 skipping and Met amp.
Development Stage	Candidate
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.